Tag: biostatistics

23 May 2017

How data influences decision-making in the health care industry

John is diagnosed with stage III colon cancer and is informed of several treatment options by his doctor. As John is not medically-trained, he does not have the medical knowledge or knowledge of new trends in treatment to decide what treatment option is the best for his specific circumstances (family history of colon cancer, 55 years of age, diabetic patient), or to decide if he needs a second opinion on treatment options. How can data help John to make an informed decision on which treatment option to select?

Pharmaceutical company A has a new treatment for colon cancer, drug X, which they want to launch. They also want to apply for funding from the medical schemes for this drug. How can data help pharmaceutical company A to show to the medical schemes that drug X is a cost-effective option compared to the current standard of care, and that drug X should, therefore, be funded by the medical schemes? Further to this, how can data help pharmaceutical company A to know in which regions to place the bulk of their sales representatives?

Pharmaceutical company B has launched a new treatment, drug Y, and wants to broaden the indication and simultaneously broaden access to patients on a lower option medical scheme. In conjunction with this, they want to show that the drug is safe and effective in real-world practice. How can data help pharmaceutical company B to reach these objectives?

Many diverse data sets are created in the health care industry. These include patient-reported outcomes, patient registries, medical schemes claims data, clinical trial data, sales data, and more.

How can this data be used to assist John and pharmaceutical companies A and B to make informed decisions?

Firstly, the outcomes that can be extracted from health care data should be considered.


Outcomes that can be extracted from health care data

A diverse set of outcomes can be extracted from health care data:

  1. From patient-reported outcomes: The subjective level of joint pain experienced because of, for instance, rheumatoid arthritis, measured via a scale such as the visual analogue scale (VAS).
  2. From patient registries: The efficacy of a drug for treating a specific patient population could be determined, considering specific patient characteristics, such as age, gender, whether the patient has diabetes, as in John’s case, etc.
  3. From medical schemes claims data: Patient journeys, for instance, the in-hospital cost of treating a patient with colon cancer. Further to this, what specific areas of costs contribute most to in-hospital cost (for instance, ICU vs general ward vs medicine cost), for patients treated with drug X compared to patients treated with drug Y?
  4. From clinical trial data: The efficacy of one drug compared to another to treat a disease. This data can further be used, in conjunction with cost data and safety (adverse event) data, to ascertain whether a specific drug, such as drug X, is cost-effective, compared to another drug.
  5. From sales data: The total number of units of a drug sold per year, and factors influencing sales, such as seasonality and the location and effort of sales staff.


Methods used to extract outcomes from health care data

A variety of methods are used to extract outcomes from health care data:

  1. From medical schemes claims data and patient-reported outcomes: Descriptive and inferential statistical analysis using tools such as Microsoft Excel or SAS.
  2. From patient registries: Big data analysis methods using statistical modelling and machine learning, such as descriptive, predictive and prescriptive analytics.
  3. From clinical trial data: A pharmacoeconomic model can be developed that uses the efficacy data, together with cost data from amongst others medical schemes claims data, to determine whether a drug or device is cost-effective, compared to a comparable drug or device (comparator). Methods used in modelling can include Markov modelling (where a disease or treatment of a disease is broken into different states, with different utilities/weights and costs related to each state), as well as newer techniques such as discrete event simulation. Further to this, clinical trial data can be analysed using biostatistics, to prove efficacy in terms of predefined primary and secondary endpoints.
  4. From sales data: Depending on the size of the data set, different methods can be used, including big data analysis methods.


How can value be extracted for the patient and pharmaceutical or device company?

Methods one to three above can be used to inform John of the best drug to use for his specific circumstances, considering both the cost and efficacy of the drug and considering his age, diabetes status and family history of colon cancer (personalised medicine).

For pharmaceutical company A, methods one to four can help to provide evidence to the medical schemes of the cost-effectiveness of drug X, and to determine where to best place different sales staff members to achieve the optimal number of sales in a specific region.

For pharmaceutical company B, methods one, two and four can help to provide evidence to broaden the indication or access for lower option scheme members. These methods can also be used to prove efficacy and safety in a real-world setting, compared to a clinical trial setting.

These examples demonstrate how value can be extracted for the patient, the pharmaceutical (or device) companies as well as the medical schemes companies. However, the scientific evidence by itself is insufficient to convince them of the value of the drug. It requires a subtle combination of science, art and communication to convert these abstract concepts into value stories that will inspire them. By combining science with art, one can communicate the value of products and/or treatments in a language that appeals to each of these stakeholders. At TCD Outcomes Research, we have termed this process as “Dynamic Solutions to Dynamic QuestionsTM”.

Follow our blog for more information and case studies on data in the health care industry. Contact us to find out how TCD Outcomes Research can assist in providing you with valuable insights from your data. Visit our website for more information.

TCD Outcomes Research is a fully fledged, full service, health economics and outcomes research (HEOR) company serving healthcare companies globally and forms part of the TCD Group. We specialise in late phase health outcomes research by studying the real world value of healthcare solutions and its economic and financial impact. Partner with us to receive a skill set on a continuum of your needs, be it market access, medical, clinical, regulatory, sales or marketing. Convert scientific evidence related to efficacy, safety and quality into a market approach that focuses on real world evidence (RWE) to communicate the value of your product to your stakeholders.

02 May 2017

TCD joins EOH as the group grows with strategic changes taking effect in May 2017

We are delighted to share the following significant changes and positive developments which took place recently within the TCD Group.

New Ownership

EOH, a JSE-listed South African based Knowledge Management group, have been in negotiation with the TCD Group since the last quarter of 2015, sharing the strategic objective to expand in the field of healthcare. EOH consists of a diverse portfolio of specialised industries in 21 countries across four continents.

The groups came to agreement in October 2016 and the transaction was completed in February 2017. EOH Holdings is now the 100% shareholder of the TCD Group of companies. We are excited by this positive development which opens many new horizons through the global profile of our new proudly South African owners.

The EOH philosophy involves sustaining successful acquisitions by building upon the inherent culture. The TCD Group will remain easily recognisable, building on our rich legacy, striving as always for continuous improvement.

Expansion of the TCD Group

The rapid evolution of the TCD Group expanded the original Triclinium into a full-service CRO (Contract Research Organisation), with a growing range of services and geographical footprint. Triclinium’s sister companies, within the TCD Group now consists of:

  • TCD Outcomes Research: The TCD Group developed a Health Economics and Outcomes Research (HEOR) organisation, through an acquisition of HeXor (a late phase development and pharmacoeconomics company), combined with the Late Phase Clinical Development expertise of TCD.
  • TCD e-Clinical Solutions: The TCD Group created an e-Clinical Solutions division which includes Software as a Service solution. TCD e-Clinical Solutions is focused around improving the outcome of clinical trials from a quality and efficiency perspective. Services include Electronic Data Capture (EDC), Electronic Medical Records (EMR), Electronic Patient Reported Outcomes (ePRO), Electronic Clinical Outcome Assessments (eCOA) and Mobile Health (mHealth), etc.
  • TCD Global Data Services: The TCD Group established and consolidated its Data Management and Biostatistics division under the TCD GDS brand, which is spearheaded out of South Africa and Bangalore, India.
  • TCD-MENA: The TCD Group established a full-service CRO based in Cairo, Egypt through a Joint Venture to focus on the Middle East and North Africa region.
  • PharmaLTX: The TCD Group established a software development company which specialises in software solutions in the wider health care sector such as partnering with Ministries of Health, Regulatory agencies, Institutional Review Boards, Universities, Clinical Research Centres, etc.


New TCD Group Chairman

The mandate to meld the member companies into a synergistic group has been entrusted to Dr Tienie Stander, founder of HeXor Pty Ltd., current Managing Director of TCD Outcomes Research, and now also the inaugural Chairman of the TCD Group.

Change in Managing Director of Triclinium Clinical Development

To those who know the company well, the most visible change is that after 17 years at the helm, founder Victor Strugo will relinquish the position of Managing Director to Abraham van Wyk, effective 1st May, 2017. Abraham has been increasingly involved in TCD executive functions since 2014 and his promotion is fully endorsed by TCD’s Board of Directors.

Victor will nevertheless remain active and visible in the new role of TCD Group Strategic Adviser, facilitating a smooth management transition, supporting key projects and developing new horizons for the company that he created in February 2000.

Our electronic media will be updated accordingly over time. We look forward to maintaining and strengthening our association with your organisation through this transition and to offer an ever-improving and broadening range of services in the years ahead.

For queries or more information, contact us at corporate.communications@tcd-global.com

31 Jan 2017

TCD MENA officially registered as CRO in Egypt

We are proud to announce that TCD MENA is now officially registered as a CRO in Egypt. Complementing TCD SA’s long-standing outreach into sub-Saharan and West Africa, TCD MENA was recently established in Heliopolis, Cairo to extend the provision of TCD’s clinical development services to clients looking to conduct research in the Middle East and North Africa (MENA) region.

The TCD MENA team has extensive clinical research experience in managing global clinical trials with sites in Egypt and the MENA region, as well as managing bioequivalence studies accepted by WHO, FDA and EU. Their expertise covers various therapeutic areas, including Oncology, Hepatology, Internal Medicine, Gynaecology and chronic diseases with strong relationships with KOLs across Egypt and the MENA region. Services include Regulatory Affairs, Clinical Operations, Project Management, Pharmacovigilance, Data Management, Biostatistics and Medical Writing.

We at TCD South Africa are excited about this long-standing partnership with TCD MENA, and in walking this road for the benefit of humanity.